Veritas In Silico Inc. (TYO:130A)

Japan flag Japan · Delayed Price · Currency is JPY
458.00
+1.00 (0.22%)
Last updated: Apr 3, 2026, 2:09 PM JST
Market Cap2.96B -45.1%
Revenue (ttm)91.14M -53.2%
Net Income-425.67M
EPS-65.62
Shares Out6.49M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,100
Average Volume17,765
Open457.00
Previous Close457.00
Day's Range456.00 - 465.00
52-Week Range428.00 - 940.00
Beta-0.75
RSI43.74
Earnings DateMay 1, 2026

About Veritas In Silico

Veritas In Silico Inc. engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA. The company has strategic partnership with Liverpool ChiroChem for the mRNA-targeted drug discovery and development. Veritas In Silico Inc. was incorporated in 2016 and is based in Shinagawa, Japan. [Read more]

Industry Surgical and Medical Instruments and Apparatus
Founded 2016
Country Japan
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 130A
Full Company Profile

Financial Performance

In 2025, Veritas In Silico's revenue was 91.14 million, a decrease of -53.18% compared to the previous year's 194.64 million. Losses were -425.67 million, 80.0% more than in 2024.

Financial Statements